Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer
Novartis will soon launch Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer.
It's for postmenopausal women whose cancer progresses despite treatment with an antiestrogen such as tamoxifen (Nolvadex).
Femara is an aromatase inhibitor. Blocking this enzyme inhibits the PRODUCTION of estrogen in peripheral tissues.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote